RNA interference (RNAi) is a biological process that inhibits gene expression. Alnylam is at the forefront of research to develop methods of treating diseases using RNAi. It is investigating the potential of small interfering RNAs (siRNAs) to silence the expression of specific defective genes by breaking down their mRNA. This stops the production of harmful proteins that cause disease.

The animation produced for Alnylam Pharmaceuticals acts as an introduction to their pipeline of investigational RNAi therapeutics, focusing on 3 main areas:
• Genetic Medicines
• Cardio-Metabolic Disease
• Hepatic Infectious Disease

This asset was primarily used to educate healthcare professionals on the complicated MoA of the RNAi therapeutics and how they act on a multitude of disease areas.

Are you interested in seeing how our award-winning medical animation can help you?

Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.